BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34702850)

  • 1. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
    Lamb LS; Pereboeva L; Youngblood S; Gillespie GY; Nabors LB; Markert JM; Dasgupta A; Langford C; Spencer HT
    Sci Rep; 2021 Oct; 11(1):21133. PubMed ID: 34702850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.
    Nabors LB; Lamb LS; Goswami T; Rochlin K; Youngblood SL
    Front Immunol; 2024; 15():1299044. PubMed ID: 38384458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
    Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
    Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
    Jin L; Kiang KM; Cheng SY; Leung GK
    Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease.
    Kubota Y; Aoki Y; Masaki N; Obara K; Hamada K; Han Q; Bouvet M; Tsunoda T; Hoffman RM
    Biochem Biophys Res Commun; 2024 Feb; 695():149418. PubMed ID: 38176171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
    Fukai J; Koizumi F; Nakao N
    PLoS One; 2014; 9(8):e104538. PubMed ID: 25111384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
    Pereboeva L; Harkins L; Wong S; Lamb LS
    Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
    Kitange GJ; Carlson BL; Schroeder MA; Decker PA; Morlan BW; Wu W; Ballman KV; Giannini C; Sarkaria JN
    J Neurooncol; 2010 Nov; 100(2):177-86. PubMed ID: 20443131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
    Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
    J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.